-
51.发明授权Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof 有权可溶性透明质酸酶糖蛋白（sHASEGP），其制备方法，用途及其组合物公开(公告)号：US07767429B2
公开(公告)日：2010-08-03
申请号：US10795095
申请日：2004-03-05
IPC分类号： C12N9/26 , A61K38/47 , C12P21/02 , C07K14/435
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
摘要翻译： 本发明涉及新型可溶性中性活性透明质酸酶糖蛋白（sHASEGP's）的发现，其制备方法及其用于促进其它分子的施用或减轻糖胺聚糖相关病理学的用途。 描述了可溶性中性活性sHASEGP结构域的微活性多肽结构域，其包括功能性中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。 包括改进的氨基末端前导肽，其增强sHASEGP的分泌。 本发明还包含重组sHASEGP的唾液酸化和聚乙二醇化形式，以增强天然存在的屠宰酶的稳定性和血清药代动力学。 进一步描述了衍生自真核细胞的基本上纯化的重组sHASEGP糖蛋白的合适制剂，其产生其最佳活性所需的适当糖基化。
-
52.发明授权Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof 有权人类软骨素酶糖蛋白（CHASEGP），其制备方法和由其组成的药物组合物公开(公告)号：US07544499B2
公开(公告)日：2009-06-09
申请号：US10539110
申请日：2003-12-15
CPC分类号： C12N9/88 , A61K38/47 , C12Y402/02004
摘要： The invention relates to the discovery of a novel Chondroitinase Glycoproteins (CHASEGP's), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal chondroitinase activity. The invention also includes carboxy-terminal deletion variants of CHASEGP that result in secreted variants of the protein to facilitate manufacture of a recombinant CHASEGP. Further described are suitable formulations of a substantially purified recombinant CHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. CHASEGP is useful for the degradation of glycosaminoglycans and chondroitin sulfate proteoglycans under clinical conditions where their removal is of therapeutic value.
摘要翻译： 本发明涉及新型软骨素酶糖蛋白（CHASEGP）的发现，其制备方法和潜在用途，其中去除硫酸软骨素可具有治疗益处。 软骨素酶糖蛋白需要CHASEGP多肽的大部分催化结构域和天冬酰胺连接的糖基化以获得最佳的软骨素酶活性。 本发明还包括CHASEGP的羧基末端缺失变体，其导致蛋白质的分泌型变体以促进重组CHASEGP的制备。 进一步描述了衍生自真核细胞的基本上纯化的重组CHASEGP糖蛋白的合适制剂，其产生其最佳活性所需的适当糖基化。 CHASEGP可用于在其去除具有治疗价值的临床条件下降解糖胺聚糖和硫酸软骨素蛋白聚糖。
-
53.发明申请Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases 审中-公开可溶性糖胺聚糖酶和制备和使用可溶性糖胺聚糖的方法公开(公告)号：US20090123367A1
公开(公告)日：2009-05-14
申请号：US11884862
申请日：2006-02-23
申请人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost , Michael F. Haller , Gilbert A. Keller , Tyler M. Dylan
发明人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost , Michael F. Haller , Gilbert A. Keller , Tyler M. Dylan
IPC分类号： A61K51/10 , C12N9/26 , A61K38/47 , A61K49/00 , A61K39/395 , A61K38/21 , A61K39/09 , A61P35/00 , A61K39/25 , A61K39/165 , A61K38/20 , A61K39/13 , A61K39/145 , A61K39/29
CPC分类号： A61K38/47 , A61K39/3955 , C12N9/2408 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
摘要翻译： 本发明涉及新型可溶性中性活性透明质酸酶糖蛋白（sHASEGPs）的发现，其制备方法及其用于促进其它分子的施用或减轻糖胺聚糖相关病理学的用途。 描述了可溶性中性活性sHASEGP结构域的微活性多肽结构域，其包括功能性中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。 包括改进的氨基末端前导肽，其增强sHASEGP的分泌。 本发明还包含重组sHASEGP的唾液酸化和聚乙二醇化形式，以增强天然存在的屠宰酶的稳定性和血清药代动力学。 进一步描述了衍生自真核细胞的基本上纯化的重组sHASEGP糖蛋白的合适制剂，其产生其最佳活性所需的适当糖基化。
-
公开(公告)号：US07321922B2
公开(公告)日：2008-01-22
申请号：US11080258
申请日：2005-03-14
申请人： Hao Zheng , Bruce Hui-der Chu , Anirban Kundu , Miles A. Libbey , David H. Nakayama , Jing Zhu
发明人： Hao Zheng , Bruce Hui-der Chu , Anirban Kundu , Miles A. Libbey , David H. Nakayama , Jing Zhu
IPC分类号： G06F15/16
CPC分类号： G06Q10/107 , H04L51/12
摘要： The invention relates to determining electronic text communication distributed in bulk is likely solicited. In one step, a first electronic and a second electronic submission are received. It is determined that the first electronic submission is likely solicited. A first portion is extracted from the first electronic submission and a second portion from the second electronic submission. The content of the first electronic submission influences extraction of the first portion, and the content of the second electronic submission influences extraction of the second portion. A first code is determined for the first portion and a second code is determined for the second portion, where the first code is indicative of the first portion and the second code is indicative of the second portion. The first code is compared to the second code. It is determined that the second electronic submission is likely solicited, at least in part, in response to comparing the first code to the second code.
摘要翻译： 本发明涉及确定批量散布的电子文本通信可能被请求。 一步，接收第一个电子和第二个电子提交。 确定可能要求第一次电子提交。 从第一电子提交中提取第一部分，并从第二电子提交中提取第二部分。 第一电子提交的内容影响第一部分的提取，并且第二电子提交的内容影响第二部分的提取。 为第一部分确定第一代码，并且为第二部分确定第二代码，其中第一代码指示第一部分，而第二代码指示第二部分。 第一个代码与第二个代码进行比较。 确定可以至少部分地响应于将第一代码与第二代码进行比较来请求第二电子提交。
-
-
-
搜索结果
54 条记录 (耗时 0.055 秒)
